Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. Zdenka E. Segota

Hematology Oncology | Hematology | Oncology
Brrh Oncology, LLC
701 Northwest 13th St, 2nd Floor, 
Boca Raton, FL 
Accepting New Patients
Offers Telehealth
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Brrh Oncology, LLC
701 Northwest 13th St, 2nd Floor, 
Boca Raton, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zdenka Segota is a Hematologist Oncology specialist and a Hematologist in Boca Raton, Florida. Dr. Segota is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Segota is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in ME
Hospital Affiliations
Boca Raton Regional Hospital
Holy Cross Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

BRRH ONCOLOGY, LLC
701 Northwest 13th St, 2nd Floor, Boca Raton, FL 33486

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice
Enrollment Status: Suspended
Publish Date: April 08, 2019
Intervention Type: Diagnostic test
View 7 Less Clinical Trials

2 Total Publications

Unusual Brain Lesions Diagnosed From a Cerebrospinal Fluid Wet Preparation in a Patient With AIDS.
Unusual Brain Lesions Diagnosed From a Cerebrospinal Fluid Wet Preparation in a Patient With AIDS.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: May 24, 2020
Similar Doctors
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Luis E. Raez
Hematology Oncology | Oncology
Elite in Non-Small Cell Lung Cancer (NSCLC)
Dr. Luis E. Raez
Hematology Oncology | Oncology

South Broward Hospital District

1150 N 35th Ave, Suite 170, 
Hollywood, FL 
 (24.1 miles away)
954-265-4325
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist Oncology specialist and an Oncologist in Hollywood, Florida. Dr. Raez is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Estelamari A. Rodriguez
Hematology Oncology | Hematology | Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Estelamari A. Rodriguez
Hematology Oncology | Hematology | Oncology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (40.2 miles away)
305-689-8648
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Estelamari Rodriguez is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Rodriguez is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Squamous Cell Lung Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration. Dr. Rodriguez is currently accepting new patients.

Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Mohammad Jahanzeb
Oncology | Hematology Oncology
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
Dr. Mohammad Jahanzeb
Oncology | Hematology Oncology
1192 E Newport Center Dr, Suite 100, 
Deerfield Beach, FL 
 (4.4 miles away)
954-571-0111
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Mohammad Jahanzeb is an Oncologist and a Hematologist Oncology provider in Deerfield Beach, Florida. Dr. Jahanzeb is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Jahanzeb is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Segota's expertise for a condition
ConditionClose
    View All 35 Advanced Conditions
    View All 133 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile